The 2026 consensus updates thyroid nodule management with clearer risk assessment, tailored biopsy decisions and more consistent follow-up strategies.
Setting off: why do we need new signposts?
The management of thyroid nodules is familiar territory for many clinicians, but the landscape is changing. Advances in ultrasound and the widespread use of cross-sectional imaging have led to a steady rise in the detection of incidental thyroid nodules. The challenge is now one of discrimination rather than detection. Most nodules are benign and many thyroid cancers are indolent, so the priority is to identify the minority requiring intervention while avoiding overdiagnosis and overtreatment.
The recently published 2026 joint consensus statement from the British Thyroid Association (BTA), the British Association of Endocrine and Thyroid Surgeons (BAETS) and collaborating bodies builds on the 2014 BTA guidelines and provides an important update to UK practice [1, 2]. This article offers a guided tour of the key updates and their implications for day-to-day practice.
"The challenge is now one of discrimination rather than detection"
First stop: a more selective approach to biopsy
One of the most pivotal changes is a more nuanced approach to fine needle aspiration cytology (FNAC). The 2014 BTA guidance recommended FNAC for U3, U4 and U5 nodules, without formally incorporating nodule size into biopsy decision-making [2]. The new consensus retains the familiar U classification but introduces size-based thresholds for selected nodules, bringing UK practice more in line with international risk-stratification [3,4]. Asymptomatic nodules measuring less than 1 cm and without suspicious clinical features may now be discharged. U3 nodules measuring 1–2 cm may undergo either FNAC or interval ultrasound depending on local policy, while U3 nodules over 2 cm should generally be considered for FNAC. Likewise, U4 or U5 nodules measuring 5–10 mm may be observed or biopsied depending on MDT policy, while nodules over 1 cm should usually be considered for FNAC (Figure 1).
Figure 1: Management of thyroid nodules according to U score and nodule size.
Clearer signposting: more structured ultrasound reporting
The 2014 BTA guidance established the need for structured sonographic reporting and embedded the U classification into routine UK practice. The 2026 statement goes further, recommending that reports clearly state the risk stratification system used, document sonographic features which justify the score, record the size and location of relevant nodules, assess both thyroid lobes and comment explicitly on central and lateral neck nodes. This goes beyond technical refinement, representing a service-level improvement to standardise reporting across operators and support more consistent MDT decision-making.
Changing direction: thyroid nodule vascularity
A notable shift concerns Doppler vascularity. In the 2014 BTA ultrasound classification, intra-nodular vascularity appeared among suspicious sonographic features. The new consensus states that vascularity is a poor standalone predictor of malignancy and should not be used as a primary feature in risk stratification. This clarification proves useful as vascularity can attract more concern in practice than the evidence justifies.
Checking the dashboard: thyroid function tests
The new statement also gives greater prominence to thyroid function testing before imaging. Serum TSH should be measured prior to ultrasound and included on the request form where available. This is more than an administrative detail. Thyroid function provides important clinical context, identifies patients who may require scintigraphy and supports cytological interpretation.
A key junction: toxic and incidental nodules
Autonomous hyperfunctioning nodules are rarely malignant, yet can produce indeterminate cytology due to their follicular architecture and hypercellularity. The new guidelines stipulate that confirmed toxic nodules should not routinely undergo FNAC. This aims to prevent unnecessary repeat biopsy or surgery in patients whose main problem is function rather than malignancy.
The guidance is also more explicit surrounding incidental nodules. Incidental nodules identified on cross-sectional imaging should be triaged using the Duke 3-tiered system before referral for dedicated ultrasound. FDG-avid thyroid lesions on PET-CT are recognised as higher-risk findings that usually merit further evaluation, unless such investigation would not alter patient care.
A clearer view: the role of core biopsy
FNAC remains the first-line pathological investigation for thyroid nodules, but the new statement clarifies more clearly where core biopsy may be useful, including suspected aggressive thyroid malignancy, lymphoma, fibrosing disease or following repeated non-diagnostic FNAC in nodules that remain suspicious. This more explicit framework should prevent both underuse and overuse; whilst core biopsy has a role, it is not a routine substitute for FNAC.
"This goes beyond technical refinement, representing a service-level improvement to standardise reporting across operators and support more consistent MDT decision-making"
Figure 2: Core members of the thyroid multidisciplinary team.
Navigating with consistency: the MDT and quality assurance
Perhaps the most service-shaping aspect of the 2026 statement is its emphasis on pathway design and governance. It recommends consultant-led thyroid nodule assessment clinics, with ultrasound and FNAC performed by appropriately trained practitioners. Additionally, it defines the core thyroid MDT (Figure 2) and specifies the minimum dataset required for discussion, including TSH, ultrasound findings, FNAC, histology and, where appropriate, cross-sectional imaging. Mandatory MDT discussion is advised for histologically confirmed thyroid malignancy, Thy4 and Thy5 cytology, discordant cases and selected Thy3a or Thy3f nodules managed outside standard pathways.
The consensus statement also brings quality assurance into sharper focus. It recommends an FNAC adequacy rate of at least 85% and encourages regular local audit and service improvement initiatives. By defining measurable standards, the statement reflects the growing recognition that consistency in pathway delivery is as important as consistency in diagnostic criteria.
Figure 3: Recommended follow-up for thyroid nodules according to U score and cytology.
The road ahead: follow-up strategies
Surveillance has long been one of the least standardised areas of thyroid nodule management. The 2014 BTA guidance generally supported discharge of benign nodules, unless specific concern was identified. The new consensus retains that principle, but adds more granular advice for low-risk nodules managed conservatively (Figure 3).
"More standardised assessment, more selective intervention and greater confidence in avoiding unnecessary biopsy, surgery and prolonged follow up"
Benign U2 nodules without compressive symptoms or clinical risk factors may still be discharged. Where follow-up is chosen for benign or low-risk nodules, repeat ultrasound at 12 months is recommended, rather than earlier scanning. The statement also suggests a minimum of two years of surveillance for unbiopsied U3 nodules and sub-centimetre U4/U5 nodules. Nodules with indeterminate or suspicious cytology managed without surgery should be followed up annually for at least five years. This more practical approach seeks to reduce variation in care and support safer, more confident discharge decisions.
The end of the tour
The 2026 consensus statement represents an evolution, rather than revolution. It preserves the familiar framework of UK thyroid nodule practice while offering clearer guidance in the areas that have generated the greatest uncertainty: small suspicious nodules, discordant imaging and cytology, toxic nodules, non-diagnostic FNAC, MDT decision-making and surveillance. Its overall message is simple: more standardised assessment, more selective intervention and greater confidence in avoiding unnecessary biopsy, surgery and prolonged follow-up. For clinicians and patients alike, this forms a welcome move from variation and uncertainty towards a more proportionate and consistent pathway.
References
1. Moorthy R, Balasubramanian SP, Farnell K, et al. Evaluation and Management of Thyroid Nodules: A Joint Consensus Statement From the British Thyroid Association (BTA), British Association of Endocrine and Thyroid Surgeons (BAETS) and Collaborating Bodies. Clin Endocrinol (Oxf) 2026;104(6):682–92.
2. Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 2014;81 Suppl 1:1–122.
3. Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid 2025;35(8):841–985.
4. Durante C, Hegedüs L, Czarniecka A, et al. 2023 European Thyroid Association Clinical Practice Guidelines for thyroid nodule management. Eur Thyroid J 2023;12(5):e230067.
Declaration of competing interests: None declared.
